Bulevirtide recently received conditional approval from the EMA for the treatment of chronic hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first case of hepatitis delta cure following 3 years of bulevirtide monotherapy in a patient with compensated cirrhosis and esophageal varices. During the 72-week off-bulevirtide follow-up, virological and biochemical responses were maintained. In the off-therapy liver biopsy, intrahepatic HDV RNA and hepatitis D antigen were undetectable, <1% of hepatocytes were hepatitis B surface antigen positive and all were negative for hepatitis B core antigen. Ishak grading and staging were improved following treatment

A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics / M.P. Anolli, E. Degasperi, L. Allweiss, A. Sangiovanni, M. Maggioni, C. Scholtes, V. Oberhardt, C. Neumann-Haefelin, M. Dandri, F. Zoulim, P. Lampertico. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 78:4(2023 Apr), pp. 876-880. [10.1016/j.jhep.2022.12.023]

A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics

M.P. Anolli
Primo
;
P. Lampertico
Ultimo
2023

Abstract

Bulevirtide recently received conditional approval from the EMA for the treatment of chronic hepatitis delta, but the ideal duration of therapy is unknown. Herein, we describe the first case of hepatitis delta cure following 3 years of bulevirtide monotherapy in a patient with compensated cirrhosis and esophageal varices. During the 72-week off-bulevirtide follow-up, virological and biochemical responses were maintained. In the off-therapy liver biopsy, intrahepatic HDV RNA and hepatitis D antigen were undetectable, <1% of hepatocytes were hepatitis B surface antigen positive and all were negative for hepatitis B core antigen. Ishak grading and staging were improved following treatment
Bulevirtide; clinically significant portal hypertension; compensated cirrhosis; HBcrAg; HBV; HDV; HDV RNA; liver fibrosis; PBMC; sustained virological response
Settore MED/12 - Gastroenterologia
apr-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0168827822034754-main.pdf

accesso riservato

Descrizione: Case reports
Tipologia: Publisher's version/PDF
Dimensione 677.04 kB
Formato Adobe PDF
677.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1001411
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 3
social impact